Table 1. Demography, baseline clinical and laboratory characteristics of the study population.
| Characteristic | All types
(n=200) |
Type I Cr.GN
(anti-GBM) (n=31) |
Type II Cr.GN
(immune complex) (n=93) |
Type III Cr.GN
(pauci-immune) (n=76) |
P value |
|---|---|---|---|---|---|
| Age (years, mean±SD) | 40.6±14.6 | 37.5±12.2 | 37.8±14.6 | 45.3±14.3 | 0.03 @, 0.003 # |
| Gender (male:female (ratio)) | 80:120 (0.67) | 12:19 (0.63) | 36:57 (0.63) | 32:44 (0.73) | 0.89 |
| Renal symptoms (n (%))
Oliguria Anuria Visible hematuria Non-visible hematuria Hypertension Uremic symptoms |
112 (56)
20 (10) 25 (12.5) 190 (95) 100 (50) 84 (42) |
23 (74.2)
5 (16.1) 6 (19.4) 29 (93.5) 15 (48.4) 20 (64.5) |
50 (53.8)
4 (4.3) 9 (9.7) 90 (96.8) 51 (54.8) 30 (32.3) |
39 (51.3)
11 (4.5) 10 (13.2) 71 (93.4) 34 (44.7) 34 (44.7) |
0.08
0.03 0.38 0.55 0.42 0.006 |
| Extra-renal symptoms (n (%))
Skin lesions Arthritis Hemoptysis |
24 (12)
40 (20) 19 (9.5) |
0
6 (19.4) 4 (12.9) |
16 (17.2)
18 (19.4) 0 |
8 (10.5)
16 (21.1) 15 (19.7) |
0.006
0.96 <0.001 |
| Diabetes mellitus (n, %) | 14 (7) | 0 | 5 (5.4) | 9 (11.8) | 0.03 |
| Hemoglobin (g/dL, mean±SD) | 8.6±2.1 | 7.6±1.9 | 9±2 | 8.5±2.1 | 0.003 $ |
| Total leucocyte (cells*10
9/L,
mean±SD) |
9.9±4.5 | 9.3±3.9 | 9.8±5.2 | 10.3±3.7 | 0.57 |
| Serum cholesterol (mg/dL, mean±SD, n) | 199.7±73.8 (123) | 205.3±101.8 (15) | 213.9±73.2 (62) | 178.8±59.6 (46) | 0.04 # |
| Serum albumin (g/dL, mean±SD) | 3±0.7 | 3.2±0.6 | 2.8±0.8 | 3.1±0.5 | 0.008 $, 0.005 # |
| 24-hour proteinuria (g/day, median
(IQR), n) |
3.5 (1.8-5.6) (187) | 3.3 (2-5.8) (26) | 4.2 (2.1-6) (89) | 2.8 (1.3-4.3) (72) | 0.06 |
| Serum creatinine (mg/dL, mean(SD) | 6.9±4.4 | 10.6±5.5 | 5.1±3.2 | 7.6±4.1 | <0.001 @$, 0.001 # |
| CKD-EPI eGFR (ml/min/1.73m
2,
median (IQR)) |
9 (5-16.8) | 5 (4-8) | 14 (8-25.5) | 7 (5-12) | <0.001 @# |
| CKD stages at baseline (n (%))
Stage 2 Yes Stage 3 Yes Stage 4 Yes Stage 5 Yes Stage 5D Yes |
7 (3.5)
19 (9.5) 34 (17) 52 (26) 88 (44) |
0
1 (3.2) 0 6 (19.4) 24 (77.4) |
6 (6.5)
13 (14) 24 (25.8) 21 (22.6) 29 (31.2) |
1 (1.3)
5 (6.6) 10 (13.2) 25 (32.9) 35 (46.1) |
|
| Serum complements (mg/dL, n/N (%))
Low C3 Low C4 |
84/196 (42.9)
21/196 (10.7) |
7/31 (22.6)
0 |
59/90 (65.6)
20/90 (22.2) |
18/75 (24)
1/75 (1.3) |
<0.001
<0.001 |
| Serology (n/N (%))
ANA Yes Anti- dsDNA Yes ANCA Yes Anti-MPO-ANCA Yes Anti-PR3-ANCA Yes |
51/176 (29)
25/146 (17.1) 54 (31.8) 28/143 (19.6) 26/143 (18.2) |
7/31 (22.6)
0 10/31 (32.3) 7/25 (28) 3/25 (12) |
38/80 (47.5)
25/75 (33.3) 6/64 (9.4) 3/50 (6) 3/50 (6) |
6/65 (9.2)
0 38/76 (50) 18/68 (26.5) 20/68 (29.4) |
<0.001
<0.001 <0.001 <0.001 <0.001 |
Abbreviations: Cr.GN, crescentic glomerulonephritis; eGFR, estimated glomerular filtration rate (calculated using the CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration formula); C3, complement C3; C4, complement C4; ANA, anti-nuclear antibody; Anti- dsDNA, anti-double stranded DNA antibody, ANCA, anti-neutrophil cytoplasmic antibody; MPO; myeloperoxidase; PR3, proteinase 3; GBM, glomerular basement membrane.
P value is significant at <0.05 between @ Type 1 and Type III, #Type II and Type III, $Type 1 and Type II analyzed by One-way ANOVA with Bonferroni correction.